Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ensysce Biosciences (ENSC) Debt to Equity (2020 - 2022)

Ensysce Biosciences (ENSC) has disclosed Debt to Equity for 3 consecutive years, with -$0.03 as the latest value for Q4 2022.

  • On a quarterly basis, Debt to Equity rose 92.23% to -$0.03 in Q4 2022 year-over-year; TTM through Dec 2022 was -$0.03, a 92.23% increase, with the full-year FY2022 number at -$0.03, up 92.23% from a year prior.
  • Debt to Equity was -$0.03 for Q4 2022 at Ensysce Biosciences, up from -$0.34 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.78 in Q1 2022 to a low of -$2.48 in Q3 2021.
  • A 3-year average of -$0.3 and a median of -$0.08 in 2020 define the central range for Debt to Equity.
  • Peak YoY movement for Debt to Equity: crashed 2854.71% in 2021, then surged 92.23% in 2022.
  • Ensysce Biosciences' Debt to Equity stood at -$0.09 in 2020, then crashed by 426.47% to -$0.45 in 2021, then soared by 92.23% to -$0.03 in 2022.
  • Per Business Quant, the three most recent readings for ENSC's Debt to Equity are -$0.03 (Q4 2022), -$0.34 (Q3 2022), and -$0.17 (Q2 2022).